Clinical Trials Browser

Recurrence × Ipilimumab × Dermatologic × Clear all

NCT02668770 2025-10-23

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Phase 1 Active not recruiting

Melanoma, Neoplasm Metastasis, Recurrence